Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis.
Sakaue S, Yamaguchi E, Inoue Y, Takahashi M, Hirata J, Suzuki K, Ito S, Arai T, Hirose M, Tanino Y, Nikaido T, Ichiwata T, Ohkouchi S, Hirano T, Takada T, Miyawaki S, Dofuku S, Maeda Y, Nii T, Kishikawa T, Ogawa K, Masuda T, Yamamoto K, Sonehara K, Tazawa R, Morimoto K, Takaki M, Konno S, Suzuki M, Tomii K, Nakagawa A, Handa T, Tanizawa K, Ishii H, Ishida M, Kato T, Takeda N, Yokomura K, Matsui T, Watanabe M, Inoue H, Imaizumi K, Goto Y, Kida H, Fujisawa T, Suda T, Yamada T, Satake Y, Ibata H, Hizawa N, Mochizuki H, Kumanogoh A, Matsuda F, Nakata K, Hirota T, Tamari M, Okada Y. Sakaue S, et al. Among authors: ibata h. Nat Commun. 2021 Feb 15;12(1):1032. doi: 10.1038/s41467-021-21011-y. Nat Commun. 2021. PMID: 33589587 Free PMC article.
Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation.
Nishimura T, Okano T, Naito M, Iwanaka S, Ohiwa A, Sakakura Y, Yasuma T, Fujimoto H, D'Alessandro-Gabazza CN, Oomoto Y, Kobayashi T, Gabazza EC, Ibata H. Nishimura T, et al. Among authors: ibata h. Thorac Cancer. 2021 Apr;12(7):1067-1073. doi: 10.1111/1759-7714.13870. Epub 2021 Feb 14. Thorac Cancer. 2021. PMID: 33586356 Free PMC article.
Is the Efficacy of Adding Ramucirumab to Docetaxel Related to a History of Immune Checkpoint Inhibitors in the Real-World Clinical Practice?
Nishimura T, Fujimoto H, Okano T, Naito M, Tsuji C, Iwanaka S, Sakakura Y, Yasuma T, D'Alessandro-Gabazza CN, Oomoto Y, Gabazza EC, Kobayashi T, Ibata H. Nishimura T, et al. Among authors: ibata h. Cancers (Basel). 2022 Jun 16;14(12):2970. doi: 10.3390/cancers14122970. Cancers (Basel). 2022. PMID: 35740634 Free PMC article.
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.
Taniguchi H, Kondoh Y, Ebina M, Azuma A, Ogura T, Taguchi Y, Suga M, Takahashi H, Nakata K, Sato A, Sugiyama Y, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Taniguchi H, et al. Respir Res. 2011 Jul 15;12(1):93. doi: 10.1186/1465-9921-12-93. Respir Res. 2011. PMID: 21756364 Free PMC article. Clinical Trial.
Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.
Azuma A, Taguchi Y, Ogura T, Ebina M, Taniguchi H, Kondoh Y, Suga M, Takahashi H, Nakata K, Sato A, Kudoh S, Nukiwa T; Pirfenidone Clinical Study Group in Japan. Azuma A, et al. Respir Res. 2011 Oct 28;12(1):143. doi: 10.1186/1465-9921-12-143. Respir Res. 2011. PMID: 22035508 Free PMC article. Clinical Trial.
40 results